Skip to main content

Table 1 Characteristics of 2638 patients hospitalized with incident Staphylococcus aureus bacteremia in Northern Denmark, 2000-2011

From: Chronic heart failure and mortality in patients with community-acquired Staphylococcus aureus bacteremia: a population-based cohort study

  Patients with chronic heart failure Patients without chronic heart failure
Numbers (%) 390 (14.8) 2248 (85.2)
Age, median (IQR) 76.6 (66.9–82.2) 67.4 (54.4–78.3)
 15–39 years 12 (3.1) 221 (9.8)
 40–59 years 48 (12.3) 557 (24.8)
 60–79 years 194 (49.7) 988 (44.0)
  ≥ 80 years 136 (34.9) 482 (21.4)
Sex   
 Men 253 (64.9) 1363 (60.6)
 Women 137 (35.1) 885 (39.4)
S.aureus bacteremia   
 Community-acquired 203 (52.1) 1320 (58.7)
 Healthcare-associated 187 (48.0) 928 (41.3)
 MRSA 3 (0.8) 10 (0.4)
Marital status   
 Married 203 (52.1) 1067 (47.5)
 Divorced or widowed 152 (39.0) 734 (32.7)
 Never married 35 (9.0) 447 (19.9)
Selected comorbid conditions   
 Diabetes mellitus 121 (31.0) 287 (12.8)
 Peripheral vascular disease 99 (25.4) 229 (10.2)
 Cerebrovascular disease 76 (19.5) 239 (10.6)
 Chronic pulmonary disease 120 (30.8) 243 (10.8)
 Moderate to severe renal disease 130 (33.3) 306 (13.6)
 Hypertension 193 (49.5) 458 (20.4)
 Conditions related to alcohol abuse 26 (6.7) 209 (9.3)
 Conditions related to drug abuse 4 (1.0) 69 (3.1)
 Dialysis within 30 days of admission 61 (15.6) 203 (9.0)
Modified Charlson Comorbidity Index   
 Low (0) 42 (10.8) 720 (32.0)
 Intermediate (1–2) 129 (33.1) 826 (36.7)
 High (>2) 219 (56.2) 702 (31.2)
Preadmission medication use   
 Immunosuppressive therapya 3 (0.8) 25 (1.1)
 Systemic antibiotic therapya 82 (21.0) 454 (20.2)
 ACE inhibitorsb 298 (76.4) 788 (35.1)
 Beta blockersb 271 (69.5) 764 (34.0)
 Acetylsalicylic acidb 301 (71.2) 820 (36.5)
 Statinsb 174 (44.6) 451 (20.1)
Clinical biochemistry   
White blood count (109/L)c   
  < 3.5 11 (2.8) 100 (4.5)
 3.5–10 52 (13.3) 440 (19.6)
  > 10 262 (67.2) 1292 (57.5)
 Unknown 65 (16.7) 416 (18.5)
  1. IQR interquartile range, MRSA methicillin resistant Staphylococcus aureus, ACE inhibitors angiotensin-converting-enzyme inhibitors
  2. aAny use within 30 days of the current admission. bAny previous use prior to the current admission
  3. cMeasured on the date the first positive blood culture was drawn